Abstract:External Quality Assurance (EQA) is vital to ensure acceptable analytical quality in medical laboratories. A key component of an EQA scheme is an analytical performance specification (APS) for each measurand that a laboratory can use to assess the extent of deviation of the obtained results from the target value. A consensus conference held in Milan in 2014 has proposed three models to set APS and these can be applied to setting APS for EQA. A goal arising from this conference is the harmonisation of EQA APS b… Show more
“…The TFG-PEQAS has recommended the use of one of the PS models from the Milan conference [24]. In agreement with Infusino et al [25], the addition of PS derived from Milan models to the EQAS categorization previously published by Miller et al [26] as criteria to evaluate the performance of laboratories participating to EQAS should be promoted.…”
Section: The Strategic Conference Heritage Eflm Initiated Task and Fimentioning
confidence: 84%
“…The TFG on Performance Specifications for EQAS (TFG-PEQAS) has identified six basic elements that need to be considered: (a) the nature of the EQAS material, including its commutability, which may affect the result interpretation; (b) the procedure used to assign the target value; (c) the data set to which PS are applied; (d) the analytical property being assessed (i.e. TE, bias, imprecision); (e) the rationale for the selection of the PS; and (f) type(s) of model used to set PS [24].…”
Section: The Strategic Conference Heritage Eflm Initiated Task and Fimentioning
confidence: 99%
“…Miller's categories 1 and 2, which fulfil the metrological requirements (commutable samples, valueassigned with reference measurement procedure), should be each split in two sub-categories: 1/2A, in which Milan models 1 and 2 for PS are applied, and 1/2B, in which other low-order models to establish PS are employed [25]. As initial steps, the TFG-PEQAS encourages EQAS organizers to provide structured descriptions of PS and to review PS providing their rationale; in a more consolidated manner, they recommend developing common EQAS PS through a collaborative process and using relevant Milan model(s), in order to support uniform performance and high quality in the total examination process [24].…”
Section: The Strategic Conference Heritage Eflm Initiated Task and Fimentioning
Abstract:Measurements in clinical laboratories produce results needed in the diagnosis and monitoring of patients. These results are always characterized by some uncertainty. What quality is needed and what measurement errors can be tolerated without jeopardizing patient safety should therefore be defined and specified for each analyte having clinical use. When these specifications are defined, the total examination process will be "fit for purpose" and the laboratory professionals should then set up rules to control the measuring systems to ensure they perform within specifications. The laboratory community has used different models to set performance specifications (PS). Recently, it was felt that there was a need to revisit different models and, at the same time, to emphasize the presuppositions for using the different models. Therefore, in 2014 the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) organized a Strategic Conference in Milan. It was felt that there was a need for more detailed discussions on, for instance, PS for EQAS, which measurands should use which models to set PS and how to set PS for the extra-analytical phases. There was also a need to critically evaluate the quality of data on biological variation studies and further discussing the use of the total error (TE) concept. Consequently, EFLM established five Task Finish Groups (TFGs) to address each of these topics. The TFGs are finishing their activity on 2017 and the content of this paper includes deliverables from these groups.
“…The TFG-PEQAS has recommended the use of one of the PS models from the Milan conference [24]. In agreement with Infusino et al [25], the addition of PS derived from Milan models to the EQAS categorization previously published by Miller et al [26] as criteria to evaluate the performance of laboratories participating to EQAS should be promoted.…”
Section: The Strategic Conference Heritage Eflm Initiated Task and Fimentioning
confidence: 84%
“…The TFG on Performance Specifications for EQAS (TFG-PEQAS) has identified six basic elements that need to be considered: (a) the nature of the EQAS material, including its commutability, which may affect the result interpretation; (b) the procedure used to assign the target value; (c) the data set to which PS are applied; (d) the analytical property being assessed (i.e. TE, bias, imprecision); (e) the rationale for the selection of the PS; and (f) type(s) of model used to set PS [24].…”
Section: The Strategic Conference Heritage Eflm Initiated Task and Fimentioning
confidence: 99%
“…Miller's categories 1 and 2, which fulfil the metrological requirements (commutable samples, valueassigned with reference measurement procedure), should be each split in two sub-categories: 1/2A, in which Milan models 1 and 2 for PS are applied, and 1/2B, in which other low-order models to establish PS are employed [25]. As initial steps, the TFG-PEQAS encourages EQAS organizers to provide structured descriptions of PS and to review PS providing their rationale; in a more consolidated manner, they recommend developing common EQAS PS through a collaborative process and using relevant Milan model(s), in order to support uniform performance and high quality in the total examination process [24].…”
Section: The Strategic Conference Heritage Eflm Initiated Task and Fimentioning
Abstract:Measurements in clinical laboratories produce results needed in the diagnosis and monitoring of patients. These results are always characterized by some uncertainty. What quality is needed and what measurement errors can be tolerated without jeopardizing patient safety should therefore be defined and specified for each analyte having clinical use. When these specifications are defined, the total examination process will be "fit for purpose" and the laboratory professionals should then set up rules to control the measuring systems to ensure they perform within specifications. The laboratory community has used different models to set performance specifications (PS). Recently, it was felt that there was a need to revisit different models and, at the same time, to emphasize the presuppositions for using the different models. Therefore, in 2014 the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) organized a Strategic Conference in Milan. It was felt that there was a need for more detailed discussions on, for instance, PS for EQAS, which measurands should use which models to set PS and how to set PS for the extra-analytical phases. There was also a need to critically evaluate the quality of data on biological variation studies and further discussing the use of the total error (TE) concept. Consequently, EFLM established five Task Finish Groups (TFGs) to address each of these topics. The TFGs are finishing their activity on 2017 and the content of this paper includes deliverables from these groups.
“…Quality parameters should be implemented across the whole laboratory network . EQA or proficiency testing (PT) monitors laboratory performance, flagging deviations in quality, and is a valuable tool for identifying and assessing the technology in use across laboratory networks . In addition, it can identify training requirements.…”
Introduction
Laboratory quality assurance (QA) includes internal quality control (IQC), external quality assurance (EQA) and quality improvement (QI). EQA identifies quality deviations and training needs. D‐dimers are breakdown products of thrombus and results guide various clinical decisions.
Methods
The National Health Laboratory Service (NHLS) in South Africa performs the pathology tests for more than 80% of the population. The NHLS Quality Assurance Department distributed 301 questionnaires to laboratories enquiring about D‐dimer testing. Two levels of STAGO® and Siemens® commercial D‐dimer assay control material were distributed for analysis and returned results analysed.
Results
A total of 64 (21.2%) completed questionnaires were returned and 26 (40.6%) laboratories were performing D‐dimers with 25 (97%) subscribing to an EQA scheme. All laboratories reported results in D‐dimer units with a negative result cut‐off of ≤0.25 mg/L but various testing platforms were in use. All returned interpretations of analyses on the blinded control material were correct. The results were also within the respective reference ranges of the controls apart from three outliers. One laboratory obtained a result on STAGO® pathological control that was above the cut‐off of the control reference range but the reason for this error could not be identified. Another obtained results on the STAGO® and on the Siemens® normal controls that were both below the cut‐off of the control reference range due to transcription errors.
Conclusion
The study demonstrated the feasibility of a local EQA scheme for D‐dimers based on commercial control material that could mitigate against the cost of international EQA scheme participation.
“…Available data from external quality assessment schemes (EQAs) highlight the need for further efforts to improve analytical performances. Clinical laboratories using standardized diagnostic systems still provide significantly different results, and appropriate analytical performance specifications for setting and monitoring analytical goals have yet to be homogenously adopted [22]. Analytical quality continues to be the "core business" of laboratory professionals, but only by raising our awareness of the inter-relationship and inter-connection between the different phases of the testing cycle can we hope to improve upon the ultimate value and quality of laboratory information.…”
In laboratory medicine, a great forward step has been taken toward the pathway to a better understanding of quality, errors and risks to patient safety. An innovative approach for identifying all possible analytical errors, and systematically evaluating errors in individual patient results, is described in the paper by Michael Vogeser and Christoph Seger "Irregular analytical errors in diagnostic testing -a novel concept", in the current issue of the journal [1].A valuable source of information and a topic for further discussion, the paper (a) focuses on the need for a patient-centered approach for evaluating analytical quality; (b) reinforces the utility of appropriate metrics for measuring and improving upon quality in the analytical phase of laboratory testing; (c) stresses the importance of adequately defining the uncertainty of laboratory results and related "allowable uncertainty"; (d) stresses that a closer clinical-laboratory interface relationship, particularly in the post-post-analytical phase, is needed for adequately identifying the nature of "irregular (individual) analytical errors" -and providing valuable explanations and defining any corrective actions required; (e) is conducive to including the monitoring of "irregular analytical errors" as an additional quality indicator of the IFCC model of the quality indicator (MQI) project [2][3][4].The authors state that an "irregular analytical error is given when a test result generated from a sample using a routine method deviates from the reference measurement procedure (RMP) results generated for this sample more than the measurement error estimate of the routine method" [1]. They also state that an irregular analytical error should be generated, particularly in immunoassays, by: a cross-reaction, sometimes with compounds not listed by the manufacturer; anti-reagent antibodies (e.g. heterophilic antibodies); interference in signalgeneration (e.g anti-ruthenium antibodies); high levels of compounds (e.g. biotin in streptavidin/biotin binding-based immunoassays); matrix protein interferences (e.g. due to immunocomplexes, rheumatoid factors) and several other matrix effects (e.g. differential impact of matrix factors on target analyte and internal standard in LC-MS assays).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.